Genetic Variants of PON1 Exhibit Associations with Dysglycemia and Metabolic Liver Risk

Overview

This study identifies specific genetic variants of PON1 that are associated with dysglycemia and metabolic liver risk, independent of enzyme activity.

Background

Paraoxonase 1 (PON1) is an enzyme linked to high-density lipoprotein (HDL) that plays a crucial role in antioxidant defense and is implicated in cardiometabolic diseases. Understanding the genetic factors influencing PON1 activity is essential, as they may contribute to dysglycemia and metabolic liver risk, conditions that are increasingly prevalent in aging populations.

Data Highlights

No numerical or trial data provided in the source material.

Key Findings

• Two PON1 variants, rs2057681 and rs854572, are major determinants of PONase activity.
• Haplotype analysis indicates that specific genetic combinations affect enzyme activity and metabolic risk.
• In carriers of the rs2057681 G allele, the C–A haplotype is linked to lower dysglycemia risk and higher metabolic liver risk.
• In rs2057681 AA homozygotes, the same haplotype shows an opposite association with metabolic liver risk.
• Despite strong genetic effects on PONase activity, enzyme activity was not directly associated with dysmetabolic phenotypes.

Clinical Implications

Clinicians may need to consider genetic variations in PON1 when assessing metabolic risks in older adults.

Conclusion

The study provides insights into the genetic regulation of metabolic risk factors associated with PON1.

Related Resources & Content

1. Archives of Toxicology, 2019 -- PON1 Enhances DNA Damage in Cells Induced by Lactone Substrates
2. The Journal of Clinical Endocrinology & Metabolism, 2025 -- Role of Peptidylglycine-alpha-amidating Monooxygenase Deficiency in the Development of Sarcopenic Diabetes Mellitus
3. Clinical Rheumatology, 2018 -- Impact of Single Nucleotide Polymorphisms rs662 and rs854860 on Paraoxonase1 (PON1) Antioxidative Function in Individuals with Rheumatoid Arthritis
4. 2. Diagnosis and Classification of Diabetes: Standards of Care in Diabetes—2026 | Diabetes Care | American Diabetes Association
5. Clinical Assessment and Management of Metabolic Dysfunction-Associated Steatotic Liver Disease | AASLD
6. EASL-EASD-EASO Clinical Practice Guidelines on the management of metabolic dysfunction-associated steatotic liver disease (MASLD)
7. The Journal of Clinical Endocrinology & Metabolism — Variations in the LMNA Gene and Their Role in Polycystic Ovary Syndrome: An Ongoing Genetic Insight
8. 2. Diagnosis and Classification of Diabetes: Standards of Care in Diabetes—2026 | Diabetes Care | American Diabetes Association
9. Clinical Assessment and Management of Metabolic Dysfunction-Associated Steatotic Liver Disease | AASLD
10. EASL-EASD-EASO Clinical Practice Guidelines on the management of metabolic dysfunction-associated steatotic liver disease (MASLD)